Abstract. Combinations are set to become the mainstay in treatment and prophylaxis of malaria due to Plasmodium falciparum. Various antimalarials have been implicated in cardiotoxicity via prolongation of the QTc interval. Atovaquone-proguanil is an effective and increasingly popular antimalarial choice when used alone or with artesunate in areas of drug resistance. We report the results of an investigation carried out on the Thai-Burmese border in 42 patients randomized to receive either atovaquone-proguanil or atovaquone-proguanil-artesunate for three days. Electrocardiographic recordings were made at baseline and one hour after each dose. There was no statistically significant change in QTc interval between baseline and any subsequent readings in either treatment group or the cohort as a whole. We conclude that atovaquone-proguanil shows no evidence of cardiotoxicity either alone or when combined with artesunate.
Increasing malaria mortality in tropical countries has been linked with an increase in resistance to affordable antimalarial drugs. 1 The use of artemisinin-based combinations is now accepted as the optimum chemotherapeutic approach for uncomplicated malaria. Atovaquone-proguanil (AP, Malarone; GlaxoSmithKline, Research Triangle Park, NC) is a relatively new combination antimalarial with atovaquone inhibiting cytochrome b and proguanil inhibiting dihydrofolate reductase. The combination has excellent antimalarial activity and no serious toxicity. 2 Its main shortcoming lies in the propensity for Plasmodium falciparum to develop rapid resistance to atovaquone via a point mutation in the gene encoding for cytochrome b. The combination of AP increases antimalarial activity through synergy, and reduces the rate of resistance to atovaquone. However, susceptibility to resistance remains. Combining AP with artesunate (AAP) allows mutual protection against resistance and confers the advantage of reducing gametocyte carriage and thus the transmission of resistant strains.
2 Antimalarials such as quinidine, quinine, 3 and halofantrine 4 have been shown to alter cardiac conduction, while studies of lumefantrine (used in combination with artemether) and of mefloquine (alone or with artesunate) have not demonstrated cardiotoxicity in humans. 5 However, this does not rule out the possibility of rare cardiac effects with lumefantrine or mefloquine. We found no published electrocardiographic studies on Malarone. Neither component of this combination has structural similarities with antimalarials known to cause cardiotoxicity. We report the results of an evaluation of the cardiotoxicity of AP alone and in combination with artesunate.
This study was part of a large randomized trial in 1999 comparing AAP with AP alone and with artesunatemefloquine (AM) in the treatment of uncomplicated P. falciparum malaria. The study population consisted of children and adults in a refugee camp as well as migrant workers from Burma and living along the Thai-Burmese border. Patients presenting to one of the camp clinics with a blood film positive for P. falciparum and meeting World Health Organization criteria for uncomplicated disease were randomly assigned to receive AP, AAP, or AM. The details of this study and its results have been published; the triple combination was more effective than AP alone and was well tolerated. 2 The study was reviewed and approved by the Ethics Committee of the Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Electrocardiographic monitoring (Autocardiner FCP-2155; Fukuda Denshi Co., Ltd., Tokyo, Japan) was conducted in 42 consecutive patients who were randomly assigned to receive either AP (15 mg/kg/day and 8 mg/kg/day, respectively, for 3 days) or AAP (artesunate at a dose of 4 mg/kg/day for 3 days). Patients assigned to the AM arm were not enrolled because this combination has already been evaluated for cardiotoxicity. 6 Informed consent was obtained from all participating adults and from the parents of children who participated. One electrocardiogram (ECG) was conducted at baseline and an additional ECG was conducted on each patient one hour after each dose. This interval between the dose and the ECG was chosen for practical reasons because patients were treated mainly on an outpatient basis. Four ECGs were conducted from each patient over a three-day period. Electrocardiographic intervals (RR, PR, QRS, QT, and QTc as calculated by Bazett's correction) were measured by the machine and verified manually. Forty-two patients were enrolled in the study (26 males and 16 females). The mean age was 24.4 years (range ‫ס‬ 6-61 years) and the mean weight 38.7 kg (range ‫ס‬ 14-60 kg). Twenty-two were randomly assigned to receive AAP and 20 to receive AP alone. A paired t-test was performed to analyze differences in QTc interval in each treatment group. Table 1 summarizes the ECG findings and Table 2 summarizes the paired t-tests comparing intervals before and after three days of treatment. There was no difference in mean ± SD QTc intervals between the two treatment groups either at baseline (419 ± 22.0 and 412 ± 22.0 milliseconds, respectively; P ‫ס‬ 0.75) or three days following treatment (413 ± 24.0 and 423 ± 23.7 milliseconds, respectively; P ‫ס‬ 0.60). There was a statistically significant decrease in heart rate (increase in RR interval) between baseline and day 3 in both groups (AAP and AP); this is postulated to be due to the defervescence with treatment and has been observed previously. 5 There was no statistically significant change in QTc interval between the baseline and any subsequent readings in the cohort as a whole or with either treatment, AP, or the AAP triple combination (P ‫ס‬ 0.48 and 0.81, respectively, by paired t-test). A mean increase in QTc of more than 25% has been used to define cardiotoxicity 4 that could lead to clinically significant arrhythmias. Percentage changes in QTc in this study were all well below this level.
Combination antimalarial therapy is becoming the rule, and in particular, AP is an increasingly popular option for treatment and prophylaxis of uncomplicated P. falciparum malaria. Previous findings that some antimalarials can prolong the QTc interval suggest that it is important to evaluate the possible cardiac interactions of combinations as well as individual drugs. In this study, no prolongation of the QTc interval was found using AP either alone or in combination with artesunate, and there was no difference in QTc interval between these two treatment groups. Such cardiotoxicity studies will continue to be important as new antimalarials and combinations become available. 
